This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Wellbutrin/SR

GlaxoSmithKline plc

Drug Names(s): Bupropion hydrochloride immediate release (IR)/sustained-release (SR)

Description: Biomedtracker has a separate entry for Wellbutrin XL.

Wellbutrin has three formulations: immediate release (three times daily), sustained released (SR, twice daily), and extended release (XL, once-daily).

Wellbutrin is an antidepressant that inhibits the reuptake of dopamine, norephinephrine, and to some extent serotonin. Its effect on dopamine is the most potent, but in actuality, it is a fairly weak reuptake blocker of all three of these, and its mechanism of action is not clear.

Deal Structure: All historical revenue for Wellbutrin is recorded under Wellbutrin/SR.


Wellbutrin/SR News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug